Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Joal D. Beane

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4160-4340; OpenAlex author ID A5078219723. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. Localized Pancreatic Cancer among Military Beneficiaries: A National Cancer Database Analysis. Co-author DOI 10.1093/milmed/usaf465↗
  2. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. Co-author DOI 10.1097/xcs.0000000000000971↗
  3. Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations. Co-author DOI 10.1007/s11605-022-05553-0↗
  4. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
  5. Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes. First author DOI 10.1097/xcs.0000000000000095↗
  6. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  7. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Last author DOI 10.1245/s10434-021-10175-y↗
  8. ASO Author Reflections: Impact of Neoadjuvant Therapy on Survival After Margin-Positive Resection for Pancreatic Cancer. First author DOI 10.1245/s10434-021-10177-w↗
  9. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular i… Co-author DOI 10.1007/s10637-014-0157-7↗
  10. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. Co-author DOI 10.1007/s11605-012-1913-7↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Timothy Michael Pawlik · 3 shared papers, 2023–2026 · strength 0.66
  2. Asmita Chopra · 3 shared papers, 2021 · strength 0.53
  3. Jordan M. Cloyd · 2 shared papers, 2023–2026 · strength 0.45
  4. Catherine H. Davis · 2 shared papers, 2022–2024 · strength 0.32
  5. Henry Anthony Pitt · 2 shared papers, 2022–2024 · strength 0.32
  6. Robert Connor Chick · 1 shared paper, 2026 · strength 0.30
  7. Patrick W. Underwood · 1 shared paper, 2026 · strength 0.30
  8. Elizabeth L. Carpenter · 1 shared paper, 2026 · strength 0.30
  9. Robert W. Krell · 1 shared paper, 2026 · strength 0.30
  10. Melissa Ellen Hogg · 2 shared papers, 2021 · strength 0.25
  11. Amer H. Zureikat · 2 shared papers, 2021 · strength 0.25
  12. Herbert J. Zeh · 2 shared papers, 2021 · strength 0.25
  13. David L. Bartlett · 2 shared papers, 2021 · strength 0.25
  14. Nathan Bahary · 2 shared papers, 2021 · strength 0.25
  15. Eduardo Esteban Montalvo-Jave · 1 shared paper, 2023 · strength 0.20
  16. Bodil Andersson · 1 shared paper, 2024 · strength 0.17
  17. Karin U. Johansen · 1 shared paper, 2024 · strength 0.17
  18. Tobias Keck · 1 shared paper, 2024 · strength 0.17
  19. Bergþór Björnsson · 1 shared paper, 2024 · strength 0.17
  20. Simone Augustinus · 1 shared paper, 2024 · strength 0.17
  21. Bobby Tingstedt · 1 shared paper, 2024 · strength 0.17
  22. Ulrich Friedrich Wellner · 1 shared paper, 2024 · strength 0.17
  23. Elizabeth Gleeson · 1 shared paper, 2024 · strength 0.17
  24. Bas Groot Koerkamp · 1 shared paper, 2024 · strength 0.17
  25. Hjalmar C. van Santvoort · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.